UniQure EPS - Earnings per Share 2013-2022 | QURE

UniQure eps - earnings per share from 2013 to 2022. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
UniQure Annual EPS
2021 $7.04
2020 $-2.81
2019 $-3.11
2018 $-2.34
2017 $-2.94
2016 $-2.93
2015 $-3.72
2014 $-2.91
2013 $-3.43
2012 $-2.19
UniQure Quarterly EPS
2022-03-31 $-1.00
2021-12-31 $0.23
2021-09-30 $-0.79
2021-06-30 $8.51
2021-03-31 $-0.91
2020-12-31 $-0.01
2020-09-30 $-1.21
2020-06-30 $-0.96
2020-03-31 $-0.63
2019-12-31 $-0.96
2019-09-30 $-0.58
2019-06-30 $-0.83
2019-03-31 $-0.74
2018-12-31 $-0.59
2018-09-30 $-0.59
2018-06-30 $-0.57
2018-03-31 $-0.59
2017-12-31 $-0.91
2017-09-30 $-0.40
2017-06-30 $-0.83
2017-03-31 $-0.80
2016-12-31 $-0.58
2016-09-30 $-0.61
2016-06-30 $-0.84
2016-03-31 $-0.90
2015-12-31 $-0.81
2015-09-30 $-1.20
2015-06-30 $-0.96
2015-03-31 $-0.75
2014-12-31 $0.00
2014-09-30 $-0.63
2014-06-30 $-0.67
2014-03-31 $-0.71
2013-12-31 $0.00
2013-09-30 $0.00
2012-12-31 $0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.668B $0.524B
UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $161.383B 9.82
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.475B 16.53
Biohaven Pharmaceutical Holding (BHVN) United States $9.944B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.681B 0.00
Emergent Biosolutions (EBS) United States $1.444B 6.18
Arcus Biosciences (RCUS) United States $1.389B 35.22
Myovant Sciences (MYOV) United Kingdom $0.879B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.509B 0.00
Gelesis Holdings (GLS) United States $0.362B 0.00
Zymeworks (ZYME) Canada $0.321B 0.00
Ambrx Biopharma (AMAM) United States $0.159B 0.00
Enzo Biochem (ENZ) United States $0.114B 23.50
SQZ Biotechnologies (SQZ) United States $0.093B 0.00